All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

The Target of Rapamycin (TOR) is a giant protein kinase that functions in two physically distinct, independently regulated complexes. TOR complex 1 (TORC1), the complex directly inhibited by rapamycin (when bound to FKBP12), is composed of TOR, raptor and mLst8, although the latter is apparently dispensable \[[@pone.0116096.ref001]--[@pone.0116096.ref003]\]. TORC1 is the major regulator of mRNA translation in all eukaryotic cells, and also controls autophagy, and transcription by all three RNA polymerases \[[@pone.0116096.ref004]\]. The regulation of TORC1 activity has been extensively studied; it is rapidly increased by numerous mitogenic and growth-promoting stimuli and by cell surface receptors and decreased by stressors of all types \[[@pone.0116096.ref004],[@pone.0116096.ref005]\]. Many of these inputs operate by modifying the activity of the Tuberous Sclerosis complex (TSC), a GTPase activator for and negative regulator of Rheb \[[@pone.0116096.ref006]\]. Rheb is a ras-like GTPase that binds directly to and activates TOR in mammalian complex 1 \[[@pone.0116096.ref007]\]. Some inputs, most notably amino acid sufficiency, regulate mTOR predominantly downstream of the TSC \[[@pone.0116096.ref008]\]. We sought to apply genome-wide RNAi technology to examine whether novel mechanisms of TORC1 regulation in mammalian cells remained to be described. As a readout of mTORC1 activity, we used the phosphorylation of the 40S ribosomal protein, S6 \[[@pone.0116096.ref009]\].

S6 phosphorylation in mammalian cells is catalyzed by the protein kinase RPS6KB1, usually called p70 S6 \[[@pone.0116096.ref010],[@pone.0116096.ref011]\], which in turn is activated by sequential phosphorylation by mTOR complex1 (most importantly at S6K1(Thr389) and PDPK1 \[[@pone.0116096.ref012],[@pone.0116096.ref013]\]. Rapamycin, at low nanomolar concentrations, strongly inhibits S6KB1(Thr389) phosphorylation, kinase activity and S6 phosphorylation in essentially all cells examined in a highly selective manner \[[@pone.0116096.ref014]\]. S6K activity is especially sensitive to decreases in mTORC1 kinase activity, as shown by the ability of mTOR ATP site inhibitors to inactivate S6KB1(Thr389)at concentrations well below those needed to cause significant dephosphorylation of 4E-BP(Thr37/Thr46), another direct mTORC1 substrate \[[@pone.0116096.ref015]\]. Whereas the very low abundance of the S6K polypeptide renders S6KB1(Thr389) phosphorylation unsuitable for high throughput immunofluorescence assays of mTORC1 activity, 40S ribosomal subunits are highly abundant and rpS6 is the most specific and best characterized substrate of S6KB1. We used immunofluorescent imaging of Ribosomal protein S6 (rpS6) phosphorylation to screen for regulators of mTOR complex 1. S6 contains up to five sites of serine phosphorylation located near the polypeptide carboxyterminus that are phosphorylated by increasing S6KB1 activity in a sequential manner, in the order Ser236, 235, 240 244, 247 \[[@pone.0116096.ref009]\]. We employed a rabbit monoclonal antibody specific for RPS6(Ser235P/Ser236P) and high content microscopy to quantify rpS6 phosphorylation in the pancreatic cancer cell line MIA PaCa-2. Applying a stringent selection, we retrieved nearly 600 genes wherein at least two RNAi gave significant reduction in S6 phosphorylation. To identify mTORC1 regulators that did not require the TSC, we examined which of the elements identified in MIA PaCa-2 cells were also required for S6 phosphorylation in TSC1 null mouse embryo fibroblasts \[[@pone.0116096.ref016]\]. Among the 534 such gene products examined in TSC1 null MEFs, RNAi pools directed against 76 mRNAs were found to reduce S6 phosphorylation significantly in 2 or 3 replicates. Surprisingly, the only elements among this cohort previously associated with the maintenance of mTORC1 activity are two of the numerous subunits of the vacuolar ATPase subunits \[[@pone.0116096.ref017]\] and DDB1, which functions as a subunit of the CUL4 E3 ligase \[[@pone.0116096.ref018]\]. RNAis against another 84 TSC1null MEF targets were observed to reduce S6 phosphorylation in only one of three replicates. However, an indication that this group also bears attention is the presence of RPS6KB1 itself, as well as MAP4K3, a protein kinase that supports amino acid signaling of mTORC1 to RPS6KB1 \[[@pone.0116096.ref019]\] and Rac1 \[[@pone.0116096.ref020]\]. The retrieval in this screen of many gene products not previously associated with altered S6 phosphorylation indicates that mTORC1 is responsive to inputs from numerous intracellular sources through mechanisms that remain to be elucidated.

Materials and Methods {#sec002}
=====================

Chemicals and Reagents {#sec003}
----------------------

General reagents were purchased from Sigma and Fisher while specific reagents were purchased from Sigma (Cycloheximide), Abcam (Thapsigargin), Calbiochem (Lactimidomycin) and Perkin Elmer (Protein labeling mix ^35^S).

Cell lines and Culture conditions {#sec004}
---------------------------------

MIA PaCa-2 cells (obtained from American Tissue Culture Collection) were cultured in Dubelcco's Modified Eagle's Medium (DMEM) (Gibco/BRL, Bethesda, MD) supplemented with 10% fetal bovine serum (FBS), Hyclone (Hyclone Laboratories, Logan, Utah), horse serum (Gibco/BRL) and 1X Penicillin/ Streptomycin. In experiments employing U2OS and Hela cells, cell culture, RNA and DNA transfection, cell extraction, immunoblotting and immunoblot quantification were carried out as described previously \[[@pone.0116096.ref015]\]. De novo protein synthesis was measured by the incorporation of medium ^35^S(Methionine+Cysteine) into TCA precipitable protein during 2 hours incubation.

Antibodies {#sec005}
----------

For siRNA screening of S6-P by immunofluorescence, S6 Ribosomal protein (Ser 235-P/236-P) rabbit monoclonal Antibody (2F9) (gift from Cell Signaling Technology), the Alexa Fluor 488 goat anti-rabbit IgG (H+L) highly cross-adsorbed (Invitrogen, Carlsbad, CA) were employed. For Western Blotting antibodies were purchased from Cell Signaling (anti-mTOR, anti-S6K-Thr^389^, anti-eIF2α-Ser^51^, anti-eIF2α, anti-4EBP-Ser^65^, anti-4EBP, anti-TSC1 and anti-TSC2), Immuno-Biological Laboratories (anti-raptor and anti-PRAS40), Abcam (anti-QARS and anti-Rheb), Proteintech (anti-LARS and anti-REDD1), Santa Cruz Biotechnologies (anti-S6K) and Sigma (anti-α-Tubulin).

siRNA screening {#sec006}
---------------

A detailed description of the methods used in the primary screen has been published \[[@pone.0116096.ref021]\]. For the primary screen, we used the whole si-genome SMARTpool RNAi library Dharmacon library consisted of 21,121 siRNA SMART pools which represent known and predicted human genes and the majority of the human genome (Dharmacon siRNA library (Human genome, G-005000--05), Thermo Fisher Scientific, Lafayette, CO). Each RNAi pool consists of four individual oligonucleotides which target a different region of the same gene.

The Dharmacon library was screened in triplicate by transient reverse transfection of siRNAs into the Mia-Paca 2 cells. Each assay plate included non-specific targeting control RNAi, the FRAP and PLK1 siGENOME SMART pools. 4l of 1M RNAis were transferred from the library stock plates to each well of 384-well assay plates by using the Velocity 11 Bravo automated liquid handling platform at a final 100nM RNAi concentration. Lipofectamine 2000(Invitrogen) was used as the transfection reagent and diluted in Opti-MEM at a 1:100 ratio. Detailed description of transfection procedures employed are found in \[[@pone.0116096.ref021]\]. On each plate, a minimum of six positive (TOR) and six negative controls (NS) were placed. Cells were incubated for 72hr at 37C and subjected to IF protocol 72hr post transfection.

### Immunofluorescence {#sec007}

Cells were initially washed with PBS (Gibco BRL, Cat No 11490) and then fixed in 4% paraformaldehyde at room temperature for 15minutes, washed 3X with PBS and subsequently permeabilized with methanol at-20C for 10 mins. Fixed cells were then blocked with a solution composed of 5% HS and 1% GS in PBS for 1 hour at room temperature. The primary PS6 antibody (0.32g) in blocking solution was then added and incubated overnight for 16hours at 4C using a shaking platform at low speed. The Alexa Fluor 488 goat anti-rabbit secondary antibody (Alexa 488; 1:1000 dilution of stock) diluted in block solution at a final concentration of 0.01mg/ml was then added. Cells were counterstained with DAPI and then washed three times with PBS.

### Imaging Acquisition and Image Quantification {#sec008}

Fixed, permeabilized cells were imaged on the High Content automated Imaging microscope ImageXpress Micro System (IXM) (Molecular Devices, <http://www.moleculardevices.com>) at 10X magnification ([Fig. 1](#pone.0116096.g001){ref-type="fig"}) and analyzed using the MetaXpress software program (Molecular Devices Inc). The Cell Scoring module was used for analysis and the primary readout for identifying hits was the percent positive cells. This assay focused on cytoplasmic staining. (For additional details see ref. [@pone.0116096.ref021]). Images were analyzed and quantified by using the MetaXpress imaging software.

![High-throughput image-based screens for genes regulating the phosphorylation of rpS6.\
A. Immunofluorescence analysis (IF) of rpS6Ser(235/236) phosphorylation. Mia-Paca 2 cells were transfected in 384-well plates with a control, nonspecific RNAis NS1 (upper panel) and (NS2) (lower panel), and RNAi pools directed at S6K, TOR and Raptor, TSC1, TSC2 and PTEN. After 72 hours they were fixed, permeabilized and stained by using a rabbit monoclonal anti-S6-P(Ser 235/236) primary antibody, detected with secondary anti-rabbit Alexa 488 antibody (green). Nuclei are stained with DAPI (blue). Representative images are shown. B. Quantitation of cytoplasmic S6-P levels. The bars indicate the % of total MIA PaCa-2 cells (estimated by nuclear count) that exhibit cytoplasmic S6-P immunofluorescence at an intensity above an arbitrary threshold (% S6-P positive cells; see [methods](#sec002){ref-type="sec"}). The z' is 0.31 for the combined use of NS1 and NS2; because NS2 gave consistently higher z' than NS1 (e.g., 0.45 vs 0.32 for the experiment shown) NS2 was used exclusively in the primary screen; error bars represent 1S.D. \* = p\<0.01. C. Flow chart of the primary screen: Summary of the screening, hit analysis and hit selection. 21,121 genes were tested using RNAis composed of pools of 4 RNAi oligos (Dharmacon Library); 72 384-well plates were screened in triplicate (See [Table 1](#pone.0116096.t001){ref-type="table"}). The criteria for a "primary positive" are described in the text ([Table 2](#pone.0116096.t002){ref-type="table"} lists genes not scored due to severe inhibition of proliferation). D. Results of the confirmation screen. From the 1046 "primary positives", 870 genes, including all 161 positive kinases and the top 709 ranked by Q ([S3 Table](#pone.0116096.s005){ref-type="supplementary-material"}), were examined in a confirmation screen wherein each of the four RNAis was tested individually. The pie chart indicates how many of the potential positive hits were confirmed by 0--4 individual siRNAs (listed in [S4 Table](#pone.0116096.s006){ref-type="supplementary-material"}).](pone.0116096.g001){#pone.0116096.g001}
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###### Genes in Tsc1 null MEFs scoring positive in 2 or more replicates.

![](pone.0116096.t001){#pone.0116096.t001g}

  Gene Symbol   GeneID   Functional Class
  ------------- -------- -----------------------------------------------------------------------------------------
  Tagln3        56370    cytoskeleton-actin binding
  Myl7          17898    cytoskeleton-myosin light chain
  Myo3b         329421   cytoskeleton-non-muscle myosin
  Tekt2         24084    cytoskeleton-spindle assembly
  Tuba3         22144    cytoskeleton-tubulin
  Dncic1        13426    cytroskeleton-Dynein subunit
  Actl6b        83766    DNA modif-transcription-chromatin remodeling
  Fen1          14156    DNA modification-flap structure-specific endonuclease 1
  Smarcal1      54380    DNA modification-SWI/SNF related matrix associated, actin dependent chromatin regulator
  Dnttip1       76233    DNA modification-terminal transferase interacting protein
  Top3b         21976    DNA modification-topoisomerase 3
  Wrn           22427    DNA modifocation-helicase
  Shfm1         20422    DNA repair via BRCA2; also protein modification and RNA export
  Ddb1          13194    DNA repair; protein ubiquitination
  Mcm5          17218    DNA replication
  Gpr1          241070   GPCR-chemerin
  Ccr3          12771    GPCR-chemokine receptor
  Gpr23         78134    GPCR-Lysophosphatidic acid
  Olfr410       258702   GPCR-olf
  Oxtr          18430    GPCR-oxytocin
  Ffar3         233080   GPCR-short chain fatty acids
  Gpr3          14748    GPCR-sphingosine 1-phosphate
  Sphk1         20698    intracellualr signaling-sphingosine-1 kinase
  Strada        72149    intracellular signaling- AMPK cofactor; STE20-related kinase adapter protein alpha
  Pla2g2e       26970    intracellular signaling- Phospholipase A variant
  Limd2         67803    intracellular signaling-binds protein kinase ILK
  Edaradd       171211   intracellular signaling-EDAR associated protein
  Gnefr         27414    intracellular signaling-exocyst-secretion regulating guanine nucleotide exchange factor
  Rgl2          19732    intracellular signaling-guanyl nucleotide exchanger for Ral GTPases
  Pla2g3        237625   [intracellular signaling-Phospholipase A variant]{.ul}
  Bmp8a         12163    ligand-
  Uvrag1        78610    membrane traffic-activates the Beclin1-PI(3)KC3 complex to promote autophagy
  Rab3a         19339    membrane traffic-Rab GTPase
  Tmem38b       52076    membrane transport---TRIC-B cation channel
  Grik5         14809    membrane transport-ionotropic glutamate receptor
  Atp6v1c1      66335    membrane transport-v-ATPase subunit
  Atp6v1h       108664   membrane transport-v-ATPase subunit
  Mfsd10        68294    membrane-transport-major facilitator superfamily domain-containing protein 10
  Cel           12613    metabolism-carboxyl ester(lipid) esterase
  Fabp4         11770    metabolism-fatty acid binding
  Ugcg          22234    metabolism-UDP-glucose ceramide glucosyltransferase
  Slc25a24      229731   mitochondria-calcium dependent ATP-Mg2 uptake to buffer mito calcium
  Gtpbp8        66067    mitochondria-GTP-binding protein 8, Gtpbp8
  Mut           17850    mitochondria-methylmalonyl CoA mutase
  Pcca          110821   mitochondria-propionyl CoA carboxylase, alpha
  Pdhx          27402    mitochondria-pyruvate dehydrogenase complex, component X
  Uqcr10        66152    mitochondria-ubiquinol-cytochrome c reductase, complex III subunit
  Mtor          56717    protein kinase
  Capn3         12335    protein modification-calpain 3
  Casp1         12362    protein modification-caspase 1
  Mmp11         17385    protein modification-matrix metalloproteinase
  Mmp12         17381    protein modification-matrix metalloproteinase
  Adamts1       11504    Protein modification-matrix metalloproteinase like
  Serpinb5      20724    protein modification-serine (or cysteine) peptidase inhibitor, clade B, member 5
  Ube2k         53323    protein modification-ubiquitin-conjugating enzyme
  Tnpo2         212999   protein traffic-cytoplamic nuclear transport
  Tmem115       56395    receptor
  Tmem121       69195    receptor
  Cd19          12478    receptor-B cell Ag coreceptor
  Fcgr4         246256   receptor-FC
  Ifitm1        68713    receptor-interferon induced transmembrane protein 1
  Cd163         93671    receptor-scavenger family
  Rps24         20088    RNA-40S ribsosomal subunit
  Nob1          67619    RNA-ribosome assembly
  Ints7         77065    RNA-snRNA biogenesis
  Urm1          68205    RNA-tRNA sulfuration-ubiquitin related modifier 1 homolog
  U2af1         108121   RNA-U2 small nuclear ribonucleoprotein auxiliary factor
  Yipf2         74766    transcription
  Zfp524        66056    transcription factor
  Batf2         74481    transcription-ATF2-like
  Ccnk          12454    Transcription-cyclin K-RNA polymerase CTD kinases
  Rax           19434    transcription-homeobox protein
  Trp53bp2      209456   transcription-proapoptotic tumor suppressor ASPP2
  Thoc7         66231    transcription-RNA export
  Ssu72         68991    transcription-RNA polymerase II subunit A C-terminal domain phosphatase
  Lypd1         72585    unknown-? Tumor suppressor

10.1371/journal.pone.0116096.t002

###### Genes in Tsc1 null MEFs scoring positive in one of three replicates.

![](pone.0116096.t002){#pone.0116096.t002g}

  Gene Symbol   GeneID   Functional class
  ------------- -------- --------------------------------------------------------------------------
  Fkbp5         14229    chaperone
  Fkbp6         94244    chaperone
  Actg2         11468    cytoskeleton-actin
  Gmfg          63986    cytoskeleton-cofilin family
  Smc1a         24061    DNA structure
  Mcm3          17215    DNA-replication
  Gpr82         319200   GPCR-lower food intake in KO
  Gpr147        237362   GPCR-neuropeptide FF
  Avpr1B        26361    GPCR-AVP
  Crhr1         12921    GPCR-CRH
  Celsr2        53883    GPCR-flamingo type EC domain
  Gcgr          14527    GPCR-glucagon
  Gpr48         107515   GPCR-LGR4
  Lhcgr         16867    GPCR-LH
  Mtnr1b        244701   GPCR-Melatonin
  Olfr15        18312    GPCR-olf
  Olfr152       258640   GPCR-olf
  Olfr42        18341    GPCR-olf
  P2ry6         233571   GPCR-pyrimidinergic
  Tact3         21338    GPCR-tachykinin
  Vipr1         22354    GPCR-VIP
  Fzd3          14365    GPCR-Wnt
  Impa2         114663   intracellular signaling-inositol(myo)-1(or 4)-monophosphatase 2
  Mapk8ip2      60597    intracellular signaling-kinase scaffold
  Plcg1         18803    intracellular signaling-phospholipase C, gamma 1
  Pde1b         18574    intracellular signaling- CM-dependent Pde1B
  Orai2         269717   intracellular signaling-Ca^++^ release-activated Ca^++^ channel
  Itpkc         233011   intracellular signaling-inositol-trisphosphate 3-kinase C
  Ikbkb         16150    intracellular signaling-NFKB pathway
  Seh1l         72124    intracellular signaling-NPC Nup107--160 complex; GATOR2 complex
  Ptpdc1        218232   intracellular signaling-protein tyrosine phosphatase domain containing 1
  Rac1          19353    intracellular signaling-small GTPase
  Bcar3         29815    intracellular signaling; SH2 domain
  Calb1         12307    intracellulat signaling-cytosolic Ca^++^ binder/buffer
  Akap7         268287   intrecellular signaling-PKA anchor protein
  Ccl4          20303    ligand-chemokine
  Vwc2          319922   ligand-secreted BMP antagonist
  Srpx2         68792    matrix-Chondroitin sulfate proteoglycan
  Dspp          13517    matrix-dentin sialophosphoprotein
  Cln3          12752    membrane structure-lysosomal
  Nsmaf         18201    membrane structure-neutral sphingomyelinase activation associated factor
  Pik4cb        107650   membrane structure-phosphatidylinositol 4-kinase, beta
  Tjp2          21873    membrane structure-tight junction protein
  Slc35f1       215085   membrane transport-?nucleotide sugars
  Slc44a4       70129    membrane transport-thiamine pyrophosphate transporter.
  Pfkfb3        170768   metabolism-6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3
  Coasy         71743    metabolism-CoA synthase
  Gpx2          14776    metabolism-glutathione peroxidase 2
  Pank4         269614   metabolism-pantothenate kinase 4
  Galntl4       233733   metabolism-polypeptide N-acetylgalactosaminyltransferase 18
  Tpk1          29807    metabolism-thiamin pyrophosphokinase 1
  Nfu1          56748    mitochondria-NFU1 iron-sulfur cluster scaffold homolog
  Aldh18a1      56454    mitochondrial-proline, ornithine and arginine biosynthesis
  Pink1         68943    mitochondrial-protein kinase
  Ufd1l         22230    protein degradation-modification
  Cdk3          69681    protein kinase-cell cycle regulation
  Irak3         73914    protein kinase-IL1 receptor associated
  Pim2          18715    protein kinase-overlaps specificity of Akt
  Ripk5         213452   protein kinase-DUSTY like
  Src           20779    protein kinase-tyrosine
  Stk23         56504    protein kinase-SRSF proteins
  Map4k3        225028   protein kinase-GLK
  Map4k1        26411    protein kinase-HPK1
  Map3k10       269881   protein kinase-MLK2
  Rps6kb1       72508    protein kinase-S6
  Cd3e          12501    receptor-T cell Ag
  Acvr2         11480    receptor-ActivinA type
  Fgfr3         14184    receptor-FGF
  Cd244         18106    receptor-NK cell
  Cd8a          12525    receptor-T cell
  Rbm12         75710    RNA binding protein
  Tdrd12        71981    RNA-piRNA biogenesis factor
  Rpp25         102614   RNA-ribonuclease P subunit
  Tnrc6         233833   RNA-RNAi and miRNA
  Tars2         71807    RNA-Tars2 threonyl-tRNA synthetase 2, mitochondrial (putative)
  Eif2b3        108067   RNA-translation initiation factor
  Bhlhb9        70237    transcription factor
  Nrbp          192292   transcription- nuclear receptor binding protein 1
  Ccdc134       76457    Transcription-Cotranscriptional regulator-? Secreted protein
  Tlx3          27140    transcription-homeobox protein
  Med25         75613    Transcription-mediator of RNA polymerase II transcription, subunit 25
  Smr3a         20599    submaxillary gland androgen regulated protein 3A
  Sbsn          282619   unknown
  Trabd         67976    unknown-TraB domain containing, TRABD

### Data Analysis and Hit Scoring {#sec009}

Analysis of RNAi screening data was performed by use of the spotfire software program licensed through TIBCO Software Inc. <http://www.tibco.com> [webcite]{.ul}; Spotfire DecisionSite 9.1.1 for Lead Discovery (TIBCO, Palo Alto, CA).

To identify hits, we used a level of "% positive cells" six standard deviations above or below that of the average value of "% positive cells" in all wells on the plate transfected with a scrambled RNAi, minimally 16 wells/plate. The z score was calculated by using the formula: $$\text{z=~}\left( \text{X-AVG} \right)\text{/}\left( \text{y*Std\ dev} \right)$$ where X = "% positive cells" value corresponding to the specific well, AVG = average value obtained from all wells on the plate transfected with a scrambled RNAi, y = the number of Std. Dev chosen, i.e., 6, \* means "times".

We selected "potential positives" ([S1 Table](#pone.0116096.s003){ref-type="supplementary-material"}) employing the following three methods of analysis: i)-Hits obtained using the results from all three replicate plates where the absolute value of the z score for the corresponding candidate was equal or above 2 using 6S.D. on at least 2 plates;(37 Plates). ii)-Hits obtained using the results of 2 plates where the absolute value of the z score for the corresponding candidate was equal or above 2 using 6S.D.-this includes plates where a third replicate was lost entirely or was technically unsatisfactory (z' \< -0.05); (15 Plates). iii)-Hits obtained by analysis of one plate-because two replicates were lost or one replicate was lost and the second technically unsatisfactory, or because one replicate showed a z' that was far superior in technical quality, with a Z' \>0.4 higher than either that of the two other replicate(s); (16 Plates). The potential positive hits were visually confirmed to exclude artifacts that may have skewed the percent positive PS6 values. Wells with out-of-focus images- obvious by visual inspection and as evident by discordance in the average total cell number among the three plates were also excluded. Genes for which the cell number was decreased by a minimum of two standard deviations corresponding to mTOR, were excluded as potential positives so as to eliminate proliferative failure for reasons other than inhibition of mTOR ([S2 Table](#pone.0116096.s004){ref-type="supplementary-material"}). Although the false negative rate cannot be estimated with accuracy, it is likely the stringent selection led to rejection of true regulators of S6 phosphorylation. In addition, the z values for the mTOR RNAi positive control averaged across the three replicate plates are more dispersed than the averaged scramble controls and \~38% are less negative than the chosen z cutoff of-2, i.e., scores that would be designated "negative" ([Fig. 2](#pone.0116096.g002){ref-type="fig"}).

![Indicators of Performance in the Primary Screen.\
A. Scatter plots comparing the percent S6-P positive cells in replicate plates for the entire screen. For each gene, the % S6-P positive cells in one plate is plotted against the value observed in a replicate plate (AvsB, AvsC, BvsC). Blue and red squares are values of %S6-P positive cells after transfection of scramble and mTOR siRNAs respectively, whereas aqua squares correspond to all other genes. The correlation coefficient (R\^2 value) range from \~0.62 to \~0.67. B. Distribution of averaged z scores for all genes across the entire screen. Scatter plot comparing the z scores (y axis), averaged for all three replicates plates (numbered on the x-axis) for all genes across the entire screen. Color coding as in A. The cutoff of z+/- 2 is highlighted. Individula plates whose z' was greatly inferior to replicates were eliminated from scoring (see Text and [methods](#sec002){ref-type="sec"}). C. Rank order plot. The averaged z-score for all replicates of all genes screened; primary positives were considered those exhibiting a z score exceeding +/- 2 in 2 or more replicates (\~75% of genes) or on one plate chosen because either it was the only plate recovered or it exhibited a z' of \>0.4 over the replicates (\~25% of genes). The position of selected genes is shown in the rectangular box.](pone.0116096.g002){#pone.0116096.g002}

For all of the wells for which the z was at or above the cut-off value (z = +/- 2), we calculate the probability corresponding to each z by using the formula $$\text{Q=}\left( \text{1-x} \right)\text{*100}$$ where x = Absolute value (1-(1-NormalDistribution(z))\*2). Subsequently, the cumulative probability considering all three assay plates that corresponds to a specific hit was obtained by taking the average of all probabilities.

### Confirmation of potential positives in the primary screen {#sec010}

For the confirmation phase, 870 of the 1046 potential positives were retested in the confirmation phase of the primary screen ([S3 Table](#pone.0116096.s005){ref-type="supplementary-material"}) using the four deconvoluted siRNAs from each SMART pool separately at 100nM concentration. A similar protocol was followed as in the primary screen and the potential positives were screened in triplicate. Each plate included a minimum of 12 wells of the NS, TOR and 2 wells of PLK1. The rate of confirmation by 2 or more individual RNAis was very similar for 75

\% of "potential positives" identified by concordance of two or more plates as compared with the 25% of "potential positives" identified based on one plate. As regards the false positive rate in the initial screen, the finding that 56 of the 870 "primary positives" failed to be confirmed by any of the individual RNAis from the initial RNAi pool provides a minimal estimate of 6.4%. The 182 "primary positives" confirmed by only 1 of 4 individual RNAis from the initial pool comprise a mixture of false and true positives in unknown proportion; assuming all to be false positive, the maximal estimate of false positive rate is 27.4% ([S4 Table](#pone.0116096.s006){ref-type="supplementary-material"}).

### Secondary screen {#sec011}

The protocol for RNAi screening in the TSC1 null MEFs was similar to that employed in the primary screen except that RNAi pools were 75nM final concentration. Also, due to the greater variance observed for the positive and negative controls, the criterion employed for positivity, i.e., a "% S6-P positive cells" two standard deviations from the mean value of the corresponding NS value, is less stringent than that used for the MIA PaCa-2 cells.

### RT-PCR {#sec012}

Total RNA was prepared using the RNeasy mini kit (QIAGEN). RNA (ug) was used for cDNA synthesis using SuperScript First-Strand Synthesis System for RT-PCR (invitrogen).

Bioinformatic analysis {#sec013}
----------------------

The Panther Classification system was used to categorize hits into molecular function, Biological processes, Protein Class \[[@pone.0116096.ref022]\] using the functional classification tool. To determine which categories were enriched in the confirmed hit gene list relative to their representation in whole human genome, the statistical overrepresentation test tool was used and p values were computed using the hypergeometric probability distribution. To access the statistical enrichment or overrepresentation of these categories for the hit genes relative to their representation in the whole human genome and the global set of genes examined in the siRNA screen by using the overrepresentation tool in panther ([Fig. 3](#pone.0116096.g003){ref-type="fig"}). Categories with a p-value of \<0.05 was considered significant. Additional databases and software programs were used to validate the results obtained by PANTHER such as: the Human Protein Reference Database (HPRD), the Ingenuity pathway database, the Biomolecular Interaction Network Database (BIND), the Genego software program.

![Classification of the "Confirmed S6-P positives" into functional groups.\
Categorization of "Confirmed S6-P positives" using the PANTHER classification system into A. Protein Class; B. Molecular Function; C. Biological Processes. D. Manual reclassification by molecular function of the non-redundant "Confirmed S6-P positives" (listed in [Supp Table 7](#pone.0116096.s009){ref-type="supplementary-material"}) comprising the subcategories of "Biological Processes overrepresented in comparison to the whole genome (shown in [S1 Fig](#pone.0116096.s001){ref-type="supplementary-material"}.)."](pone.0116096.g003){#pone.0116096.g003}

Results {#sec014}
=======

Primary screen- MIA PaCa-2 human Pancreatic adenocarcinoma-derived cells {#sec015}
------------------------------------------------------------------------

The MIA PaCa-2 cell line was chosen for the high throughput screen because of its constitutively high rpS6 phosphorylation levels \[[@pone.0116096.ref023]\], suitability for immunofluorescent imaging ([Fig. 1A](#pone.0116096.g001){ref-type="fig"}), adequate transfectability and predictable proliferative behavior. They are a hypotriploid human cell line whose modal chromosome number is 61. Sixteen to 20 marker chromosomes are commonly found in a cell. A few normal chromosomes are absent. These cells have a KRasG12C mutation and KRas depletion is proapoptotic. There is also loss of CDKN2A and a p53 (R248W) gain-of-function \[[@pone.0116096.ref024]\] oncogenic mutation that inhibits ATM catalyzed DNA repair \[[@pone.0116096.ref025]\].

### RNAi Screening {#sec016}

21,121 genes were screened in triplicate using pools containing 4 RNAi oligonucleotides. Scramble RNAi against a non-specific targeting sequence served as the negative control and mTOR RNAi as the positive control \[[@pone.0116096.ref021]\]. Wells were scored by estimation of the % of cells (DAPI-stained nuclei) whose cytoplasmic rpS6-P fluorescence exceeded a value, optimized to yield the highest signal/noise ratio and optimal plate Z'. Wells containing scramble RNAi averaged 50--60% %S6-P positive cells, whereas those containing mTOR RNAi averaged 5--10% S6-P

positive cells ([Fig. 1B](#pone.0116096.g001){ref-type="fig"}). Experimental wells scored as positive were those showing a % S6-P positive cells that was higher or lower than the averaged % S6-P positive cells of the scramble wells on the same plate by a z equal or greater than +/-2, calculated using 6S.D. The screen was performed in triplicate and those genes scoring positive on two or three plates were considered "potential positives" and accounted for 75% of all "potential positives." Approximately 25% of the "potential positives" were called on the basis of one plate, either because it was the only replicate remaining or because one plate was far superior in technical quality (z' of \>0.4 over the replicates), usually because the discounted replicates plates exhibited wide variance in the values for the scramble RNAi ([S1 Table](#pone.0116096.s003){ref-type="supplementary-material"}).

To exclude the possibility that knockdown of the putative TOR regulators causes toxicity, and to correct for decreased viability effects induced by RNAis we normalized for total cell number as measured by DAPI. Hits for which the average total cell number was 2 S.D. below the average total cell number corresponding to the mTOR positive control were excluded and considered to cause mTOR-independent proliferative failure.

The 95 targets of these RNAi pools ([S2 Table](#pone.0116096.s004){ref-type="supplementary-material"}) included for e.g.,10 proteins of the 40S ribosomal subunit, several RNA splicing factors, proteasome subunits. These criteria yielded 1046 "potential positives" ([Fig. 1C](#pone.0116096.g001){ref-type="fig"}) of which 220 RNAis resulted in increased rpS6 phosphorylation. It is likely that the relatively high baseline rpS6 phosphorylation levels in the MIA PaCa-2 cells biases against identification of targets whose depletion results in increased S6 phosphorylation.

### Confirmation of potential positives {#sec017}

All 1046 "potential positives" were ranked by the Q value which represents the probability of a hit occurring by chance considering all replicate values ([S3 Table](#pone.0116096.s005){ref-type="supplementary-material"}, first tab). Of these, 870 were chosen for retesting with each of the four individual RNAi oligonucleotides comprising the original pool; this included all 161 "potential positives" from the kinase collection and strongest 709 of the remaining "potential positives." Consequently, 176, lower confidence "potential positives" were not further evaluated ([S3 Table](#pone.0116096.s005){ref-type="supplementary-material"}, second tab). In addition, potential positives among the genes identified only by LOC (\~2177), FLJ (\~450; <http://flj.lifesciencedb.jp/top/>) or ORF (\~1120) designations (see [S1 Table](#pone.0116096.s003){ref-type="supplementary-material"}) were excluded from further analysis. Here again we used a criterion of altered % positive cells exceeding a z score of +/-2, which corresponds to 6S.D. the value observed for the scramble RNAi. Six hundred thirty two of 870 (72.6%) were confirmed in 2, 3 or all 4 out of 4 individual RNAi ([Fig. 1D](#pone.0116096.g001){ref-type="fig"}). These are henceforth considered as confirmed "S6-P positives" ([S4 Table](#pone.0116096.s006){ref-type="supplementary-material"}).

### Reproducibility of replicate plates and data quality {#sec018}

Some features of the data derived from the primary screen are shown in [Fig. 2](#pone.0116096.g002){ref-type="fig"}. Comparison of the "% positive S6-P" scores observed between plates yielded R^2^ values of 0.67 (AvsB) and 0.65 (BvsC) and 0.61 (AvsC), an acceptable level of concordance ([Fig. 2A](#pone.0116096.g002){ref-type="fig"}). A plot of the z value for all of the replicate plates used for scoring the primary screen, as described above, shows that whereas the averaged z values of replicate plates for the scramble RNAis tend to cluster tightly around zero, the averaged z values for the mTOR RNAi positive control are much more dispersed ([Fig. 2B](#pone.0116096.g002){ref-type="fig"}). A plot of all 21,121 genes according to the average z value is shown is shown in [Fig. 2C](#pone.0116096.g002){ref-type="fig"} (and listed in [S5 Table](#pone.0116096.s007){ref-type="supplementary-material"}).

### Confirmed and proposed regulators of PS6 & mTORC1 {#sec019}

It is of interest to examine how confirmed and proposed regulators of S6 phosphorylation and/or mTORC1 performed in the primary RNAi screen. The raw values for %S6-P positive cells and corresponding z for selected candidates are shown in Table S6. Among the core elements, the RNAi pools for S6K1B, mTOR and TSC2 scored as "potential positives"; S6K1B and mTOR but not TSC1 were confirmed in 2 or more individual RNAis. The TSC1 RNAi pool produced an increase in %S6-P positive cells to nearly the same level as did TSC2, but failed to qualify as a "potential positive" due to an insufficient z. Although the RNAi pools directed at Rheb \[[@pone.0116096.ref007]\] and RhebL1 gave considerable reduction in %S6-P positive cells, as with TSC1 the low z scores (corresponding to Rheb and RhebL1 knockdown) prevented their designation as hits. As regards raptor/KIAA1303, two of the three replicates were lost and although this RNAi pool was effective, as shown in [Fig. 1B](#pone.0116096.g001){ref-type="fig"} no inhibition was induced by this RNAi pool in the single high throughput replicate. Although the RNAi pools for RagA and RagC \[[@pone.0116096.ref026],[@pone.0116096.ref027]\] depressed the %S6-P positive cells, none of the z values for any of the Rag GTPases RNAis reached the cutoff. The RNAi pools directed at each of the five Ragulator/LAMTOR subunits \[[@pone.0116096.ref028],[@pone.0116096.ref029]\] and that for VPS39/hVAM6 gave no decrease in the %S6-P positive cells. The GATOR 1 complex (nprl2/nprl3/DEPDC5) is reported to be a negative regulator of amino acid-stimulated, Rag dependent mTORC1 activation, whose inhibitory effect is relieved by the GATOR2 complex (Sec13/Mios/WDR24/ WDR59/SEH1L) \[[@pone.0116096.ref030]\]. RNAi toward GATOR1 components did not significantly increase %S6-P positive cells and paradoxically, DEPDC5 RNAi strongly reduced %S6-P positivity, although with a z far less than-2. Among the five components of GATOR2, only the RNAi pool directed at SEH1L gave significant inhibition of %S6-P positive cells, which was strongly confirmed with the individual RNAi. Other elements reported to regulate mTORC1 include putative positive regulators MAP4K3 \[[@pone.0116096.ref019]\], SQSTM1/p62 \[[@pone.0116096.ref031]\], V-ATPase \[[@pone.0116096.ref017]\], PAT1/SLC36A1 \[[@pone.0116096.ref032]\], folliculin/FNIP1 \[[@pone.0116096.ref033]\] and the negative regulator SH3-BP4 \[[@pone.0116096.ref034]\]. Among this latter cohort, the RNAi pools for MAP4K3, SQSTM1 and the v-ATPase subunits V1H and V1C were confirmed "S6-P positives."

### Bioinformatics {#sec020}

The 632 confirmed "S6-P positives" were analyzed using the PANTHER program \[[@pone.0116096.ref022]\] and their distribution according to Protein Class, Biologic Process and Molecular Function is displayed in [Fig. 3](#pone.0116096.g003){ref-type="fig"}. Twenty five Protein Classes are represented ([Fig. 3A](#pone.0116096.g003){ref-type="fig"}). The subcategories of GPCRs, transmembrane receptors, protein kinases/transferases and transporters are overrepresented among the "S6-P positives" as compared to the entire genome ([S1 Fig](#pone.0116096.s001){ref-type="supplementary-material"}.). Approximately 80% of the "S6-P positives" from the Biologic Processes ([Fig. 3B](#pone.0116096.g003){ref-type="fig"}) and Molecular Functions ([Fig. 3C](#pone.0116096.g003){ref-type="fig"}) fall into 3--6 broad categories. Further analysis of the subcategories comprising Molecular Functions identified the same functional subgroups found to be overrepresented in the Protein Class group ([S1 Fig](#pone.0116096.s001){ref-type="supplementary-material"}.). However, further analysis of the "S6-P positives" within "Biological Processes" identifies more numerous and seemingly diverse subcategories ([S1 Fig](#pone.0116096.s001){ref-type="supplementary-material"}.). Because these subcategories of Biologic Processes contain overlapping components, we identified the 217 nonredundant "S6-P positives" in those subcategories ([S7 Table](#pone.0116096.s009){ref-type="supplementary-material"}) and manually reclassified them by molecular function ([Fig. 3D](#pone.0116096.g003){ref-type="fig"}). Not surprisingly, GPCRs and other receptors again comprise nearly half of these elements followed by intracellular signaling proteins, especially protein kinases.

### Confirmed "S6-P positives" are enriched in "mTOR essential" genes {#sec021}

Seeking independent verification that the "confirmed S6-P positives" are enriched in regulators of mTORC1 we utilized the Achilles dataset \[[@pone.0116096.ref035]; release 2.4.1 available at [www.broadinstitute.org/achilles](http://www.broadinstitute.org/achilles))\] which enabled an inquiry of how shRNA mediated depletion of "confirmed S6-P positives" affects the proliferation/viability of a large number of cancer cell lines in comparison to depletion of mTOR. Among the 632 "confirmed S6-P positives," 193 have been analyzed in 216 cell lines. For each gene in this subset of "confirmed S6-P positives" its essentiality in each of the 216 cell lines was determined \[[@pone.0116096.ref036],[@pone.0116096.ref037]\] and matched against the essentiality profile for mTOR itself ([Fig. 4](#pone.0116096.g004){ref-type="fig"}) using as association statistic the normalized mutual information \[[@pone.0116096.ref038]\]; nominal p-values and False Discovery Rates (FDR) were computed using an empirical permutation test. From the 193 "confirmed S6-P positives," 43 were found to match the mTOR essentiality profile in the 216 cancer cell lines at the 0.05 False Discovery Rate (FDR) level of significance. To assess whether the finding that 43 of 193 "confirmed S6-P positives" exhibit coessentiality with mTOR at this level of significance (FDR \< 0.05, IC \> 0.298) exceeds what would be expected from a random set of 193 genes, we applied a hypergeometric distribution test to the 6143 genes in the Achilles 2.4.1 dataset and obtained a p-value of 0.0025. Thus the randomly chosen subset of 193 "confirmed S6-P positives" is significantly enriched in genes whose depletion affects the viability of 216 cell lines in a manner paralleling that caused by mTOR depletion. Inasmuch as depletion of these 193 genes also suppresses S6 phosphorylation, we conclude that "confirmed S6-P positives" are significantly enriched in regulators of mTORC1.

![Confirmed S6-P positives whose depletion affects the viability of a panel of cell lines similar to that of mTOR depletion.\
This heat map shows the standardized essentiality profiles (blue more essential, red less essential) of 43 S6-P positives genes that are also significantly associated (FDR \< 0.05) with mTOR essentiality (left). The association is determined by the normalized mutual information (IC score, nominal p value and FDR are shown at the top).](pone.0116096.g004){#pone.0116096.g004}

In addition, the co-essentiality association revealed by this analysis indicates that cancer cell lines more sensitive to mTOR RNAi knockout are similarly sensitive to knockout of the 43 specific genes displayed in [Fig. 4](#pone.0116096.g004){ref-type="fig"}. These genes might help delineate a state characterized by co-dependency of mTOR and the respective S6-P positive genes in regards to cell proliferation and viability.

Secondary screen-TSC1 null mouse embryo fibroblasts {#sec022}
---------------------------------------------------

### Confirmation of S6-P positives in a secondary screen {#sec023}

In an effort to select among the large number of confirmed "S6-P positives" for further analysis, and to minimize the impact of technical factors, e.g., RNAi efficacy, protein target abundance and half-life, etc. we designed a secondary screen to determine which among the elements important for S6 phosphorylation in Mia PaCa-2 cells was important to the maintenance of phospho-S6 in a line of spontaneously immortalized TSC1 null mouse embryonic fibroblasts (MEFs) \[[@pone.0116096.ref016]\]. The high basal median S6-P positivity of TSC1 null MEFs ([Fig. 5](#pone.0116096.g005){ref-type="fig"}) interdicts evaluation of MIA PaCa-2 "S6-P positives" that increase S6-P, however this secondary assay, in addition to employing different RNAis in different cell backgrounds and requiring conservation of function across human and mouse, presumably eliminates stimulatory inputs acting through TSC and focuses attention toward pathways whose inputs are more likely to act between Rheb-GTP and rpS6-P.

![Performance Properties of the siRNA Screen using TSC1 null MEFs.\
A. Representative Immunofluorescence images of rpS6Ser (235/236) phosphorylation in TSC1 null MEFs transfected with nonspecific (NS) or mTOR-directed siRNAs. The cells were stained with DAPI (blue) and for rpS6(Ser 235P/236P) (green) as in [Fig. 1A](#pone.0116096.g001){ref-type="fig"}. B. Quantitation of "%S6-P positive cells" for the TSC1 null MEFs treated with nonspecific (NS) or mTOR-directed siRNAs. Values represent the average of 42 replicate wells +/- 1S.D, for each NS and mTOR siRNA; \*p = 0.05 based on two-tailed student's t-test. C. Comparison of MiaPaCa cells (upper three plots) and into TSC1 null MEFs (lower three plots) for "%S6-P positive cells" after transfection with nonspecific (blue squares) and mTOR (red squares) siRNA. Scatter plots comparing the positive (mTOR) and negative (NS) controls among replicate plates The MEFs exhibit higher average initial "%S6-P positive cells" but less potent and more variable suppression of "%S6-P positive cells" by mTOR siRNA.](pone.0116096.g005){#pone.0116096.g005}

Mouse RNAi pools corresponding to 534 (see [S8 Table](#pone.0116096.s010){ref-type="supplementary-material"}) of the 632 confirmed S6-P positives in the MIA PaCa-2 screen were available and were tested in triplicate. As compared with MIA PaCa-2 cells, the TSC1-null MEFs exhibit higher median "%S6-P positive" cells ([Fig. 5A-C](#pone.0116096.g005){ref-type="fig"}), but a more variable and less robust suppression of "%S6-P positive" cells in response to mTOR RNAi ([Fig. 5C](#pone.0116096.g005){ref-type="fig"}, compare the red squares in the upper panels to those in the lower panels). This likely reflects less efficient and more variable transfection and results in a smaller dynamic range of S6 phosphorylation. We therefore applied a less stringent selection criterion as compared with the MIA PaCa-2 cells, i.e. altered rpS6-P \>2S.D. from the scramble on at least 2 out of the 3 replicate plates, which yielded 76 hits ([Table 1](#pone.0116096.t001){ref-type="table"}); an additional 84 scored positive on 1/3 plates ([Table 2](#pone.0116096.t002){ref-type="table"}).

Three of the mRNAs that showed significantly reduced %S6-P positive in 2 or 3 of 3 replicates (henceforth called MEF2/3 positives) (Shfm1, Urm1 and Atp6v1c1), in addition to Tor, are orthologous to genes identified by Parsons et.al. \[[@pone.0116096.ref039]\], whose deletion confers rapamycin sensitivity in haploid strains of S. cerevisiae. Both the MEF 2/3 positives ([Table 1](#pone.0116096.t001){ref-type="table"}; U2af1, Mcm5, Ddb1 and Ptpn18) and the MEF single positives ([Table 2](#pone.0116096.t002){ref-type="table"}; Eif2b3, Rac1, Rps6kb1, Coasy) include 4 genes that exhibit "co-essentiality" with mTOR in the Achilles database ([Fig. 4](#pone.0116096.g004){ref-type="fig"}).

### Glutamine tRNA synthase/QARS {#sec024}

We were intrigued by the finding that depletion of Glutamine tRNA synthase/QARS gives strong inhibition of S6-P in MIA PaCa-2 cells and is also high on the list of genes whose depletion affects the proliferation of the Achilles cancer cell cohort in a manner similar to mTOR depletion ([Fig. 4](#pone.0116096.g004){ref-type="fig"}). In contrast, RNAi directed at Leucyl tRNA synthase, which has been previously reported as a positive regulator of TORC1 \[[@pone.0116096.ref040]\], did not give significant inhibition of S6-P. Similar results were observed in U2OS and HeLa cells ([Fig. 6A](#pone.0116096.g006){ref-type="fig"}, top): in U2OS, 90--95% reduction of QARS reduced amino acid-stimulated S6K(T389) phosphorylation by 70--80%, whereas 85--90% depletion of LARS gave a 0--25% reduction ([Fig. 6A](#pone.0116096.g006){ref-type="fig"}, bar graphs). Despite the marked depletion of both QARS and LARS, the phosphorylation of eIF2α (Ser51) was not increased. The latter is an indication that the accumulation of uncharged tRNA, if any, was insufficient to activate the GCN2 kinase ([Fig. 6A](#pone.0116096.g006){ref-type="fig"} bottom). Depletion of either QARS or LARS did not alter levels of the Rheb, mTOR, raptor, or S6K polypeptides, nor was the abundance of the very short-lived polypeptide REDD1 diminished ([Fig. 6A](#pone.0116096.g006){ref-type="fig"}). These findings suggested that RNAi-induced depletion of these AARSs did not reduce protein synthesis. Although, this held true subsequent to LARS depletion, the same effect on protein synthesis was not observed for QARS depletion. Depletion of QARS polypeptide from serum and nutrient replete U2OS inhibited protein synthesis by 65--75% as measured by ^35^S-Met+^35^Cys incorporation into protein ([Fig. 6B](#pone.0116096.g006){ref-type="fig"}). QARS depletion led to inhibition of overall protein synthesis and S6K phosphorylation (T389-P), whereas comparable depletion of LARS inhibited neither. The differential effects on protein synthesis between the two AARS raised the question of whether reduced S6K phosphorylation (T389-P) caused by QARS depletion is due to the inhibition of protein synthesis. Brief treatment of cells with the inhibitor of global mRNA translation cycloheximide is known to activate mTORC1 \[[@pone.0116096.ref041]\], although the effect of sustained inhibition of protein synthesis of a magnitude comparable to that corresponding to QARS depletion is not known. U2OS cells incubated with cycloheximide (10μM for 3 days, to match the duration siRNA treatment) exhibit an 80--90% reduction in total protein accumulation as compared with cells incubated with carrier alone. Under these conditions, the relative abundance of S6K and Rheb are radically reduced, but phosphorylation of the mTORC1-catalyzed sites S6K (T389) is fractionally increased: a similar pattern is observed with lactidomycin, a selective inhibitor of translational initiation (not shown). Sustained but nonselective inhibition of protein synthesis does not inhibit and may activate mTORC1, an effect previously attributed to either an accumulation of cellular amino acids \[[@pone.0116096.ref041]\] or to loss of the TSC activator REDD1 \[[@pone.0116096.ref042]\]. It remains to be determined whether the inhibition of mTORC1 by QARS depletion reflects the loss of an mTORC1 activator(s) whose abundance is selectively sensitive to depletion of QARS (or Urm1) or to some non-translational action of QARS.

![siRNA-mediated depletion of QARS inhibits mTORC1 signaling.\
A. The effect of mTOR, QARS and LARS siRNA upon polypeptide knockdown and S6K-Thr^389^ phosphorylation. U2OS and Hela cells were transfected with siRNA oligos against mTOR, QARS (Q1,Q2), LARS(L1,L2) and a scramble control. After 72h amino acids were withdrawn for 2 hours and added back for 15 minutes as indicated. Cells extracts were subjected to SDS-PAGE and membranes were immunoblotted with the antibodies as indicated. The bar graphs display the combined results of three experiments (mean-/+ 1 S.D.; \*\* = p\<0.0001 and \* = p\<0.002 vs scramble) The experiment shown in the bottom panels compares the effects of Thapsigargin (10M) with the indicated siRNAs on S6K-P (fourth from top), eIF2α(Ser51-P) (third from bottom) and the abundance of REDD1 (bottom). B. siRNA-mediated depletion of QARS inhibits global protein synthesis. Graphical representation of the combined results from three experiments (mean-/+ 1 S.D.) examining the effect, relative to scramble siRNA, of siRNA against mTOR, QARS and LARS on the abundance of the target polypeptides (upper), the relative phosphorylation of S6K-P (middle; \*\* = p\<0.0001 and \* = p\<0.002 vs scramble) and on overall protein synthesis (bottom) in nutrient and serum replete U2OS cells. Analyses were carried out three days after transfection. ^35^S\[Methionine+cysteine\] was added two hours before harvest; cycloheximide (CHX, 100μM) or carrier was added 30′ prior to ^35^S. C. The effect of inhibiting translation for three days on mTORC1 signaling. Graphical representation of a dose response of cycloheximide (CHX) on global protein synthesis in U2OS cells. U2OS cells were plated in DMEM with 10% FCS +/- CHX and fresh media containing carrier or CHX was added every 24 hours for 72 hours. The cell were harvested at 72 hours; protein content expressed as a fraction of carrier control is plotted in the upper graph. Immunoblots of cell extracts for the proteins indicated are shown in the middle and the ratio of S6K-P/S6K (mean-/+ 1 S.D.) is shown in the bar graph at the bottom.](pone.0116096.g006){#pone.0116096.g006}

Discussion {#sec025}
==========

Primary screen {#sec026}
--------------

The recovery of a subset of the known elements crucial for S6 phosphorylation together with the significant enrichment of the confirmed "S6-positives" among the genes whose essentiality parallels that of mTOR in a large cohort of cancer cell lines supports the view that the 642 genes identified in the primary screen for regulators of S6 phosphorylation are in fact enriched in regulators of mTOR complex 1. The most heavily enriched categories among the "S6-P positives" retrieved in the primary screen are the cell surface receptors, followed by intracellular signaling proteins, especially protein kinases. An enrichment of protein kinases among the "S6-P positives" is not surprising, inasmuch as multiple protein kinases are known to contribute to S6 phosphorylation, especially mTOR, RPS6KB1 and PDPK1 \[[@pone.0116096.ref013]\], which together with mTOR complex1 catalyzes RPS6KB1 phosphorylation and activation \[[@pone.0116096.ref012]\]. IKK \[[@pone.0116096.ref043]\] and PIM2 \[[@pone.0116096.ref044]\], known inhibitors of the TSC Rheb GAP activity, MAPK11/p38βwhich activates mTORC1 in response to arsenite by phosphorylation of raptor \[[@pone.0116096.ref045]\] and MAP4K3/Glk, which is implicated in amino acid regulation of mTORC1 \[[@pone.0116096.ref019]\] are among the S6-P positives as is Casein Kinase 2, which through its action on TEL2, is perhaps important for mTOR complex assembly \[[@pone.0116096.ref046]\]. Based on published literature, thin but plausible explanations can be inferred for several other of the protein kinases retrieved (e.g., PKC, PKC, PKA, BRSK2/SADA and six tyrosine kinases). Nevertheless, the mechanisms by which depletion of the many other protein kinases (ser/thr) diminishes S6 phoshorylation are not yet evident. The finding that S6 phosphorylation is influenced by an unexpectedly large number of protein kinases raises the possibility that a regulatory network far more complex than that currently envisioned operates upstream of RPS6K1B. Alternatively, despite the relatively high statistical stringency applied to hit selection, the possibility that many of these S6-P positives are in fact not regulators of S6 phosphorylation in the MIA PaCa-2 cells, i.e., are false positives, cannot be discarded.

The recovery of 83 GPCRs among the "S6-P positives" in the primary screen (e.g., [Fig. 3D](#pone.0116096.g003){ref-type="fig"}) was not anticipated. Also retrieved were the GPCR-specific intracellular signaling elements Transducin/GNAT2, Gsα/GNAS, GNB1,3 and 5, GNG3, 5 and 7 and beta arrestin-1/ARRB1. A GPCR regulated pathway to mTORC1 in MiaPaCa cells might operate through Gβγ activation of PI-3 kinaseγ/PI3KCG (an S6-P positive) or via β-arrestin recruitment of Src (also an S6-P positive) \[[@pone.0116096.ref047]\]. As there are nearly 800 GPCRs in the human genome, including nearly 400 olfactory receptors, some are likely to be retrieved as false positives in a primary screen. Nevertheless, the prevalence of GPCRs among the S6-P positives exceeds by several fold their representation in the human genome (\~13% vs \~4%) and the basis for this enrichment is not known.

Secondary screen {#sec027}
----------------

A relatively small number of perturbations have been shown thus far capable of inhibiting mTORC1 signaling in TSC null cells, including H2O2, sorbitol \[[@pone.0116096.ref048]\], energy stress (through AMPK phosphorylation of raptor \[[@pone.0116096.ref049]\] or PRAK phosphorylation of Rheb(Ser130) \[[@pone.0116096.ref050]\]) and withdrawal of ambient amino acids \[[@pone.0116096.ref051]\], through an incompletely understood mechanism that involves the RagA or B/C or D heterodimeric GTPases \[[@pone.0116096.ref026],[@pone.0116096.ref027]\].

Focusing on the targets in the TSC1-null MEFs confirmed on 2 or more of 3 replicates ([Table 1](#pone.0116096.t001){ref-type="table"}, [S2A Fig](#pone.0116096.s002){ref-type="supplementary-material"}.), this cohort has proportionately fewer GPCRs (9%) as compared with the confirmed "S6-P positives" from the MIA PaCa-2 cells (13%), and apart from mTOR no protein kinases; however, the 84 targets confirmed on only one of three replicates ([Table 2](#pone.0116096.t002){ref-type="table"}) includes 14 GPCRs (so that GPCRs comprise 13% of combined MEF "S6-P positives,") and 11 protein kinases, including S6KB1 and MAP4K3/Glk ([S2B Fig](#pone.0116096.s002){ref-type="supplementary-material"}.). The MEF2/3 cohort does include a diverse array of non-kinase signaling molecules that, with the exception of Stradα, have no known connection to mTORC1 signaling. Stradα is a pseudokinase scaffold necessary for the activity of Lkb1, an upstream activator of AMPK. Stradα depletion from mouse neural progenitor cells activates mTORC1 through loss of AMPK activity \[[@pone.0116096.ref052]\]. Inasmuch as AMPK inhibits mTORC1 both by activation of TSC \[[@pone.0116096.ref006]\] and by direct phosphorylation of raptor \[[@pone.0116096.ref049]\], it is unclear why depletion of Stradα inhibits S6 phosphorylation in TSC1null MEFs.

Among the MEF2/3 positives with a prior connection to mTORC1 are the v-ATPase subunits V1C1 and V1H, the ubiquitin-like polypeptide Urm1 and the WD40 domain protein DDB1; we have examined the relation of the vATPase subunits and URM1 with mTORC1 in additional experiments.

### v-ATPase subunits V1H & V1C {#sec028}

The retrieval of v-ATPase subunits V1H and V1C as confirmed "S6-P positives" both in the MIA PaCa-2 cells and in the TSC1null MEFs is supportive of the role of the v-ATPase as a positive upstream mTORC1 regulator \[[@pone.0116096.ref017]\]. We confirmed the ability of RNAi to V1H (but not V1C1) to inhibit S6K(T389P) in U2OS cells (not shown). These v-ATPase subunits, which regulate rotation of the ATPase assembly, are on the cytoplasmic side of the lysosome and thus available to mTORC1. However we have been unable to detect a specific role for V1H and V1C subunits in mTORC1 localization or activation. In experiments not shown, we found that binding of recombinant V1H with coexpressed mTOR, raptor, Rheb or the Rag heterodimers is not detectable, whereas recombinant V1C1 proved generally sticky. Similarly overexpression of V1H and V1C1 does not modify the phosphorylation of co-expressed S6K in the presence or absence of amino acids, either when these v-ATPase subunits are expressed as the wild type polypeptides, or when directed to the relevant subcellular compartment either by carboxy terminal fusion of the Rheb carboxy terminal 15 amino acids, or amino terminal fusion of the p18/LAMTOR1 amino terminal 18 amino acids. Thus, the mechanism by which the v-ATPase promotes mTORC1 activity and the specific role of these subunits, if any, requires further study.

### URM1 {#sec029}

The retrieval of the ubiquitin-related modifier polypeptide Urm1 as a MEF 2/3 positive merited additional consideration both because of its unique dual function as both a protein and tRNA modifier and because its deficiency in S. cerevisiae has been shown repeatedly to confer sensitivity to rapamycin \[[@pone.0116096.ref039],[@pone.0116096.ref053]\]. Activation of Urm1 occurs though the sequential action of NFS1, a cysteinyl sulfurase that thiolates a cysteine on the E1-like enzyme MOCS3. In turn MOCS3 cleaves the URM1 carboxterminal Gly-Gly in an ATP dependent manner, adenylating Urm1 and adding it covalently as a thiocarboxylate \[[@pone.0116096.ref054]\]. Urmylated MOCS3 can react with -lysine on proteins in response to oxidative stress \[[@pone.0116096.ref055]\] by a mechanism and specificity that are unknown, or via the mediation of the cytosolic thiouridylase CTU1-CTU2, thiolate uridine at position 34 (the wobble base of the anticodon) of the Glu, Gln and Lys tRNAs \[[@pone.0116096.ref054]\]. Notably, S. cerevisiae strains lacking Urm1, Uba4(MOCS3), Ncs6(CTU1) and Ncs2(CTU2) each exhibit rapamycin sensitivity \[[@pone.0116096.ref039]\]. Urm1 deficient strains can be rescued with the rapamycin-resistant TOR2(S1972I) mutant \[[@pone.0116096.ref056]\] in S. cerevisiae, or by overexpression of the Glu/Gln/Lys tRNAs, especially in combination in either budding \[[@pone.0116096.ref053]\] or fission \[[@pone.0116096.ref057]\] yeast. These findings point to an important role for mistranslation in the genesis of the rapamycin sensitivity.

In the primary and confirmation MIA PaCa-2 screens, both the RNAi pool against *URM1* and all of the four individual RNAi oligonucleotides led to strong inhibition of S6 phosphorylation. In subsequent experiments, URM1 knockdown by RNAi decreased S6K phosphorylation at Thr 389 in U2OS cells (not shown). The RNAi pools against *NFS1* and *CTU1* also gave strong inhibition of S6-P but with an insufficient z, whereas the RNAi pool against *MOCS*3 gave no inhibition and an RNAi pool against *CTU2* was not included in the screen ([S1 Table](#pone.0116096.s003){ref-type="supplementary-material"}). Because of these ambiguous results regarding the elements required for URM1 activation and U34 thiolation, we reexamined the impact of the original RNAi pools in comparison to *mTOR* RNAi. In eight experiments (data not shown) wherein mTOR RNAi inhibited S6-P in MIA PaCa-2 cells with z ≤ -2 each time, the RNAi pools for *NFS1*, *MOCS3*, *CTU1* and *CTU2* did so in 7/8, 5/8, 8/8 and 4/8 experiments, respectively. In the TSC1null MEFs the RNAi pool against *Urm1* gave strong inhibition of S6 phosphorylation, however this proved to be attributable to one of the four individual RNAis. We therefore examined an additional eight individual RNAis directed at *Urm1* in the TSC1null MEFs; altogether 3/12 RNAis gave consistent inhibition of S6 phosphorylation. Moreover, RNAi pools against *Mocs3*, *Ctu1* and *Ctu2* did not reduce S6-P in TSC1 null MEFs (data not shown). We concluded that the failure of U34 thiolation contributes to the inhibition of S6 phosphorylation in MIA PaCa-2 cells, presumably through mistranslation at one or more of the codons for Gln, Glu or Lys in one or more unknown proteins. In contrast to MIA PaCa-2 cells, URM1 deficiency does not impair mTORC1 signaling in TSC1 null MEFs.

### DDB1 {#sec030}

Interestingly, DDB1 is among the few mouse orthologs retrieved that overlaps with the dTORC1 regulators retrieved by Lindquist et.al. \[[@pone.0116096.ref058]\] from a genome wide dsRNA screen for S6-P regulators in Drosophila cells. Although first identified in the repair of UV-induced DNA damage, DDB1 is also a component of the CUL4 ubiquitin ligase, whose depletion has been previously shown to inhibit S6 and 4E-BP phosphorylation while upregulating Akt(Ser473) phosphorylation. CUL4 promotes the degradation of REDD1 and TSC2, however these events are irrelevant to mTORC1 regulation in the TSC1 null MEFs. Recently, it has been shown that the DDB1-CUL4 ubiquitination of raptor is required for the stability of the mTOR complex1 \[[@pone.0116096.ref018]\]. It is unclear whether the loss of this function of DDB1 accounts for the ability of DDB1 RNAi to inhibit S6 phosphorylation, inasmuch as the RNAi pools against the other components of this ubiquitin ligase, CUL4A and RBX1/ROC1, did not inhibit S6 phosphorylation in MIA PaCa-2 cells ([S1 Table](#pone.0116096.s003){ref-type="supplementary-material"}).

Other categories of S6-P regulators in TSC1 null MEFs {#sec031}
-----------------------------------------------------

### Mitochondrial Proteins {#sec032}

Among the 76 MEF2/3 positives are 6 mitochondrial proteins ([Table 1](#pone.0116096.t001){ref-type="table"}). Among the mRNAs showing significantly reduced %S6-P in 1 of 3 MEF replicates were another four encoding mitochondrial proteins as well as the cytosolic proteins required for coenzyme synthesis, i.e. CoenzymeA Synthase/COASY, Pantothenic acid kinase-4/PANK4 and Thiamine phosphokinase/TPK1 ([Table 2](#pone.0116096.t002){ref-type="table"}). CoenzmeA Synthase has been detected in a stable complex with S6KB1, but overexpression of COASY does not affect S6K activity and S6K does not phosphorylate COASY \[[@pone.0116096.ref059]\]. We have not determined whether depletion of these elements affects ATP content or activates AMPK. In addition, Duran et.al. \[[@pone.0116096.ref060]\] reported that the inhibition of mTORC1 signaling to S6K1 engendered by withdrawal of leucine could be rescued by provision of esterified versions of αKG. Depletion of Glutamate Dehydrogenase (GLUD1) did not inhibit S6 phosphorylation in Mia-Pa Ca 2 cells. Nevertheless, propionyl CoA carboxylase/PCCA and methylmalonyl CoA mutase, both of which were confirmed in 2/3 positives in the MEFs ([Table 1](#pone.0116096.t001){ref-type="table"}) constitute an anaplerotic pathway that generates succinate from valine, isoleucine and odd chain fatty acids. Tumor cells utilize a variety of anaplerotic mechanisms to replace the TCA intermediates diverted to macromolecular synthesis \[[@pone.0116096.ref061]\] and those of most importance to MIA PaCa-2 cells remains to be determined.

### DNA repair related hits {#sec033}

The considerable number of MEF2/3 positives concerned with DNA structure and repair (Tables [1](#pone.0116096.t001){ref-type="table"},[2](#pone.0116096.t002){ref-type="table"}) is unexpected and raises consideration regarding the relationship between DNA damage and mTORC1 activity. DNA damage uniformly inhibits mTORC1 by ATM/P53/TSC activation \[[@pone.0116096.ref062]\], although doxyrubicin-induced DNA damage is reported to activate mTORC1/S6K through p38α and TSC \[[@pone.0116096.ref063]\]. These responses however are presumably inoperative in the TSC1 null MEF screen. It is possible that the disordered genetic background of MiaPaCa cells and the TSC1 null MEFs creates a context in which DNA modification and/or repair is required to sustain S6 phosphorylation. However, the underlying mechanism and physiologic relevance of this phenomenon are unknown.

Conclusion {#sec034}
==========

A genome wide screen for S6 phosphorylation has uncovered a large number of gene products whose depletion reduces mTORC1 signaling. Previously identified regulators have been retrieved, including a number whose orthologues are also necessary for optimal TORC1 signaling in S. cerevisiae, as well as many genes not previously associated with mTORC1 regulation. Additional work will be required define the specific biochemical pathways that link these elements to mTOR complex 1. Imasmuch as many cancers exhibit mTOR hyperactivation, the identification of previously unappreciated proteins needed for maintenance of mTORC1 activity may provide new drug targets and lead to the development of beneficial therapies for tumors sensitive to mTOR inhibition. The 43 genes found to match the mTOR essentiality profile in the 216 different cancer cell lines represented in the Achilles dataset may help delineate a more general cellular state characterized by co-dependency with mTOR. This finding provides the rationale for selecting this set of genes for further analysis as candidate drug targets and for investigating synthetic lethal relationships with known mTOR inhibitors.

Supporting Information {#sec035}
======================

###### Identification of the PANTHER categories overrepresented among the confirmed "S6-P positives" from MiaPaCa cells.

The 632 confirmed "S6-P positive" human genes were analyzed by PANTHER according to Biological Processes, Molecular Function and Protein Class and the subcategories that are enriched over their abundance in the genome are shown, ranked by the---log p value. A non-redundant list of the 217 specific genes comprising the categories shown under Biological Processes is provided in Supplemental [S7 Table](#pone.0116096.s009){ref-type="supplementary-material"}, and their distribution by Molecular Function is shown in [Fig. 3D](#pone.0116096.g003){ref-type="fig"}.

(TIF)

###### 

Click here for additional data file.

###### Classification by Molecular Function of the S6-P positives identified in TSC1-null mouse embryo fibroblasts.

A. Functional categories of S6-P positives confirmed in 2 or more replicates, corresponding to [Table 1](#pone.0116096.t001){ref-type="table"}. B. Functional categories of S6-P positives confirmed in one of three replicates, corresponding to [Table 2](#pone.0116096.t002){ref-type="table"}. C. Functional categories of S6-P positives confirmed in any replicate, corresponding to the combined sets in Tables [1](#pone.0116096.t001){ref-type="table"} and [2](#pone.0116096.t002){ref-type="table"}.

(TIF)

###### 

Click here for additional data file.

###### Results of primary screen in MiaPaCa cells.

Primary screen, arranged by plate. Avg.% S6P positive shown for each replicate plate. N = scramble RNAi (negative control); P = mTOR RNAi (positive control); X = experimental RNAi.

(XLSX)

###### 

Click here for additional data file.

###### RNAi pool positives excluded because cell numbers were reduced \>2S.D. below cell number seen with mTOR RNAi.

Primary S6P positives not retested due to reduced cell number \> 2SD below the mTOR RNAi on plates used for scoring. N = scramble RNAi (negative control); P = mTOR RNAi (positive control); X = experimental RNAi.

(XLSX)

###### 

Click here for additional data file.

###### 1046 "primary S6P positives" from MiaPaCa cells.

**Sheet A:** Primary positives chosen for retesting with 4 individual RNAi-see [Supp Table 4](#pone.0116096.s006){ref-type="supplementary-material"}; results shown here are from initial testing with RNAi pool **Sheet B: Primary S6P positives not retested with individual RNAis.** Primary S6P positives NOT selected for retesting with the 4 individual RNAi used in the intial screen.

(XLSX)

###### 

Click here for additional data file.

###### Results of retesting 870 "primary S6P positives" with individual RNAis.

Number of RNAi scoring positive.

(XLSX)

###### 

Click here for additional data file.

###### All genes scored in primary screen ranked by avg. z or Q.

Rank by avg. z of all genes, including only the plates used for scoring.

(XLSX)

###### 

Click here for additional data file.

###### Performance of putatively known mTORC1/S6-P regulators in primary Screen.

The effect of RNAi pools directed against putatively known regulators of S6-P in the MiaPaCa cell primary screen. Blue identifies plates not included in the scoring due to unacceptably low plate z' values.

(XLSX)

###### 

Click here for additional data file.

###### Genes comprising the PANTHER subcategories of "Biological Processes" that are overrepresented in comparison to the whole genome (See [S1 Fig](#pone.0116096.s001){ref-type="supplementary-material"}.).

The nonredundant MiaPaCa genes contained in the overrepresented subcategories of Biological Processes (see [S1 Fig](#pone.0116096.s001){ref-type="supplementary-material"}.) classified by Molecular Function in [Fig. 3D](#pone.0116096.g003){ref-type="fig"}.

(XLSX)

###### 

Click here for additional data file.

###### 534 genes tested with RNAi pools in TSC1 null Mouse Embryonic Fibroblasts.

RNAi corresponding to 98/632 "confirmed S6P positives" identified in the primary screen were unavailable.

(XLSX)

###### 

Click here for additional data file.
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